Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AN2 Therapeutics, Inc. issued 8,245,611 shares of common stock to certain investors for $2.85 per share.
- Security
- common stock
- Shares
- 8,245,611 shares
- Purchaser
- certain investors
- Consideration
- $2.85 per share
Exact text from the filing
of 5,789,493 shares of Common Stock (the “Pre-Funded Warrants,” and, together with the Shares, the “Securities”) (collectively, the “Private Placement”). The price per Share is $2.85, and the price per Pre-Funded Warrant is $2.84999. The closing of the Private Placement is expected to occur on March 10, 2026 (the “Closing”). The Pre-Funded Warrants have an
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AN2 Therapeutics, Inc. issued 5,789,493 shares of Common Stock of warrant to certain investors for $2.84999 per Pre-Funded Warrant.
- Security
- warrant
- Shares
- 5,789,493 shares of Common Stock
- Purchaser
- certain investors
- Consideration
- $2.84999 per Pre-Funded Warrant
Exact text from the filing
of 5,789,493 shares of Common Stock (the “Pre-Funded Warrants,” and, together with the Shares, the “Securities”) (collectively, the “Private Placement”). The price per Share is $2.85, and the price per Pre-Funded Warrant is $2.84999. The closing of the Private Placement is expected to occur on March 10, 2026 (the “Closing”). The Pre-Funded Warrants have an
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
AN2 Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $40 million (effective 2026-03-08).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors
- Value
- approximately $40 million
- Effective
- 2026-03-08
Exact text from the filing
On March 8, 2026, AN2 Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”).
View on SEC.gov